Meeting Abstract
ASH Highlights and Commentary: Multiple Myeloma
Kathryn T. Maples, PharmD, BCOP
Emory University, Atlanta, Georgia
J Adv Pract Oncol 2022;13(suppl 2):7-13 |
https://doi.org/10.6004/jadpro.2022.13.2.10 |
© 2022 Harborside™
ABSTRACT
This supplement to JADPRO provides an overview of several abstracts that were presented at the 2021 ASH Annual Meeting, along with expert commentary that aims to contextualize the information presented at ASH for the advanced practitioner.
Kathryn T. Maples, PharmD, BCOP, of Emory University, evaluates data on antibody therapy, which has become a critical component in the treatment of multiple myeloma. Dr. Maples reviews outcomes of multiple myeloma patients after progressing on a bispecific antibody and the efficacy and safety profiles of two BCMA- and CD3-targeting bispecific antibodies, elranatamab and teclistamab.
On the JADPRO website, you’ll find several short videos on these important abstracts that the faculty members filmed on site. Visit advancedpractitioner.com/highlights to continue the experience!
For access to the full length article, please
sign in.
